Letting the Data Tell the Story
In our previous post we described the technique for assigning categories to data, based on input from content experts within a “training database”. This technique is effective for summarizing large,...
View ArticleUsing NLP Data to Classify Patient Segments in Clinical Trial Data
One of the most common and powerful approaches in NLP provides the content experts an opportunity to label each data segment for a portion of the dataset and then analyze these labels to apply to the...
View ArticleFinding the Needle in a Haystack with NLP
The problem with Big Data is that it is so Big! This issue is especially true in the world of healthcare and drug development. It is difficult to see across all the good clinical/scientific work...
View ArticleClik here to view.
China Reshaping the Clinical Trial Pipeline
Finally, the data is in here at OZMOSI, and we can start tracking and reporting on the clinical development expected to come out of China. Gone are the days of developing drugs only in the US and...
View ArticleClik here to view.
The Clinical Trial Powershift
Pharmaceutical companies are being pushed aside when it comes to who is driving clinical outcomes. Despite the growing number of industry trials year over year, the pharmaceutical industry is taking a...
View ArticleClik here to view.
New Developments in Alzheimer’s Treatment
OZMOSI’s predictions for where Alzheimer’s treatment is headed. The Ravaging Effects of Alzheimer’s The devastation of living with an Alzheimer’s diagnosis is exponentially affecting more and more...
View ArticleClik here to view.
Uncovering New Catalyst Events in the Pharmaceutical and Biotech Markets
The Challenges with Predicting Catalyst Events “Chasing headlines” for catalyst events in the biotech and pharmaceutical markets is a common frustration of investing in these spaces. Predicting these...
View ArticleClik here to view.
Using Data to Optimize Clinical Trial Recruitment
The Importance of a High-Performing Clinical Trial Partnership Pharmaceutical companies are heavily dependent on clinical trials to assist with the placement, promotion, and sales of their products....
View ArticleClik here to view.
FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations...
FDA Expedited Drug Development Programs The Food and Drug Administration (FDA) follows an established and lengthy approval process that ensures patients have access to therapeutic agents proven to be...
View ArticleHealthiest States Index of The USA 2023
Health and wellness are pivotal for leading a wholesome life. Good health is a blessing. Time and health are the two most precious assets for human beings. Good health provides better possibilities...
View ArticleClik here to view.
New Faces in Big Pharma & the Rise of the Billion Dollar Deal
M&A mania is here. Unprecedented deal values for mergers and acquisitions dominated in 2014. Worldwide M&A was up 47% since 2013 with 95 deals valued greater than $5 billion, as reported by...
View ArticleELI LILLY in the Diabetes Market
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and...
View ArticleClik here to view.
Novo Nordisk Diabetes Pipeline Analysis
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in...
View ArticleMerck Diabetes Pipeline Analysis
Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular...
View ArticleClik here to view.
Keeping up with the Pharmaceutical Industry in Asia
Keeping up with the pharmaceutical landscape around the world, especially in Asia, is essential in today’s market. Here are some of the biggest news stories emerging from Asian countries that are...
View ArticleWhat do the big players have in store for the Diabetes market in the next 12...
Diabetes is one of the most prevalent diseases in the U.S., afflicting over 29 million people across Type 1 and Type 2 patients, according to the CDC1 and represents over a $50 billion dollar...
View ArticleClik here to view.
Covid-19 Clinical Trials and Where to Get Treated Update
Here is a quick update on the ever-evolving world of COVID-19 trials. Since our initial posting on this topic three weeks ago, the number of trials has grown from 100 to over 300. The number of...
View ArticleUsing NLP Data to Classify Patient Segments in Clinical Trial Data
One of the most common and powerful approaches in NLP provides the content experts an opportunity to label each data segment for a portion of the dataset and then analyze these labels to apply to the...
View ArticleClik here to view.
When Good Things DON’T Come to Those Who Wait: How Pharma Companies Compare...
Predicting when a competing product will be approved is essential in any commercial forecast and for any business insights team with their eye on the market. Here at OZMOSI, we have been spending our...
View ArticleLetting the Data Tell the Story
In our previous post we described the technique for assigning categories to data, based on input from content experts within a “training database”. This technique is effective for summarizing large,...
View Article
